SHIFT 45+
Core & Pro
A two-tier women's wellness gummy line for the women whose #1 problem is hot flashes. Pro AM/PM Kit leads the funnel. Core serves the budget tier.
Internal Strategy Document · 2026Contents
Chapter IExecutive Summary
A women's wellness gummy line designed for the sixty-two percent of women aged forty-five and above whose number-one problem is hot flashes — and the multiple secondary pains that arrive with them.
Customer research with three hundred personas surfaced a decisive insight: hot flashes are the dominant pain (62% rank it #1), weight gain is secondary (18%), and joint pain comes third (10%). Seventy-two percent of customers prefer the multi-mechanism Pro AM/PM Kit over the simpler Core variant — and revenue per acquisition is fifty-nine percent higher on Pro.
SHIFT 45+ launches as a two-tier line led by Pro:
- SHIFT 45+ Pro AM/PM Kit (LEAD SKU) — 3 gummies daily at $79 retail. Two morning + one evening — the AM gummy for metabolism, the PM gummy for hot flashes, sleep, and skin recovery. Drives 75% of unit volume.
- SHIFT 45+ Core (budget alternative) — 2 gummies daily at $49 retail. Same hero actives as Pro at compressed doses. Drives 25% of unit volume, serves the price-sensitive segment.
The line targets the world's fastest-growing women's health category. The global menopause supplement market reached USD 983 million in 2024 and is projected to grow to USD 24 billion by 2030. The category recently saw its first major exit — Pharmavite acquired Bonafide Health for USD 425 million in September 2024 — and Wile raised USD 111 million to enter Whole Foods nationwide.
Three hero ingredients carry the brand story: Kudzu S-equol 10mg (58.7% hot flash reduction in published RCT, non-soy fermented), Berbevis® Berberine Phytosome 1,100mg (the morning metabolic hero), and Affron® Saffron 28mg (perimenopausal mood and sleep). The remaining sixteen actives — including KSM-66 Ashwagandha, MenaQ7 K2, Cinnulin PF, and Mengtai's twelve-strain patented probiotic — support the hero trio without competing for the spotlight.
First-year revenue target is USD 2.6 million blended ($1.95M Pro + $650K Core) at ~25,000 Pro Kits and ~8,000 Core bottles, scaling to USD 12 million by year three — aligned with the Bonafide acquisition-comp benchmark. The launch begins in the United States via Meta-only paid acquisition, expanding through the United Kingdom, Germany, Italy, France, and the Nordics in months five through eight.
Chapter IIMarket Opportunity
The menopause supplement category is experiencing a generational shift in cultural permission, consumer education, and capital deployment.
Category Size & Growth
| Metric | Value | Source / Year |
|---|---|---|
| Global menopause supplement market (2024) | $983 million | Future Market Insights |
| Projected total menopause market by 2030 | $24 billion | Industry research, 2025 |
| Compound annual growth rate (H1 2025-2035) | 5.6% | vs 5.3% the prior period |
| US share of global market | ~55% | Industry estimate |
| TikTok #menopausetok growth year-over-year | 540% | 2024-2025 cultural inflection |
Category-Defining Moments (Recent)
- September 2024 — Pharmavite acquires Bonafide Health for $425 million (exit-multiple comparable now set)
- September 2025 — Bonafide enters Target retail nationwide, marking the mass-channel inflection
- 2024 — Wile raises $111 million in venture funding, expanding into Whole Foods
- January 2023 — O Positiv launches MENO, the first menopause gummy in market
- June 2025 — Valerie's "Peri-Paradox" campaign wins NutraIngredients awards for boldest peri-menopause marketing
Menopause was a whispered category in 2019. It became a $425 million exit in 2024. By 2030, it will be a $24 billion industry. The product launched now lands in a market that is finally ready to talk back.
Chapter IIICompetitive Landscape
No incumbent owns the multi-mechanism category. Each leading brand stakes a single claim. SHIFT 45+ Max consolidates twelve.
| Brand | Position | Price (USD) | Active Count | SHIFT-45+ Advantage |
|---|---|---|---|---|
| Bonafide Thermella | Hot flash (curcumin-led) | $60 | 3 | 4× more actives at competitive price |
| Bonafide Relizen | Hot flash (pollen extract only) | $35-60 | 1 | Multi-mechanism vs single-symptom |
| Equelle (Pharmavite-Otsuka) | S-equol only, soy-source | $43-60 | 1 | Non-soy S-equol + 11 other actives |
| Goli ACV | Apple cider vinegar mass | $25 | 1 | 12× the active depth |
| Estroven Complete | Mass-market menopause | $25 | 4 | Full dose disclosure, no proprietary blends |
| Thorne Meta-Balance | Clinician-channel premium | $45-55 | ~6 | Patent-named heroes vs generic actives |
| Momentous Berberine | Single-active metabolic | $50 | 1 | Double the berberine dose at competitive price |
| Nutrafol Women | Hair-loss premium | $88 | ~6 | Different category — non-competing |
Positioning Verdict
The category is fragmented by symptom focus. Bonafide owns "hot flash". Goli owns "ACV". Equelle owns "S-equol". None own "the full perimenopause body shift in one bottle."
SHIFT 45+ Max claims the entire transition — weight management, hot flashes, sleep, mood, bone, and metabolic stability — at a price point that beats Bonafide by ten dollars while offering four times the active ingredients.
Chapter IVProduct Strategy
Three distinct gummy formulas. Two consumer variants. One central thesis — the body changes; the protocol should change with it.
Three Hero Ingredients (the brand-story stars)
| Hero | Daily Dose (Pro Kit) | What it does |
|---|---|---|
| 🌙 Kudzu S-equol — the moat | 10 mg PM | Otsuka 2012 trial in 114 postmenopausal women: 58.7% hot flash reduction vs 34.5% placebo, p<0.01. Fermented from kudzu root (non-soy) via Lactococcus 20-92. Works for the 65-80% of Western women who are equol non-producers. |
| 🌅 Berbevis® Berberine Phytosome | 1,100 mg AM | PCOS trial 2023: -5.2% body weight, 70% menstrual regularity restoration, -23.5% free testosterone in 90 days. 9.6× absorption vs standard berberine. |
| 🌙 Affron® Saffron (Spain) | 28 mg PM | 2021 perimenopausal trial in 86 women: 33% nervousness reduction, 32% mood improvement at 12 weeks. No estrogenic effects. |
These three carry every brand message. The remaining sixteen actives — KSM-66, ALA, inositol, ACV, cinnamon, EGCG, D3, K2, magnesium, B6, folate, twelve-strain probiotic, prebiotic, lemon oil, vitamin C, fermented rice bran extract — appear on the supplement-facts panel but not in the headlines. This kills the "kitchen-sink" perception flagged by sixteen percent of customer research respondents.
Three Gummy Formulas, Two Variants
| Formula | Used In | Daily Intake | Active Mass / Gummy |
|---|---|---|---|
| ① Core Gummy | Core variant | 2 gummies with breakfast (identical) | ~1.55 g |
| ② Pro AM Gummy | Pro Kit | 2 gummies with breakfast (identical) — metabolic stack | ~1.70 g (highest load) |
| ③ Pro PM Gummy | Pro Kit | 1 gummy with dinner — sleep, hot flash, beauty stack | ~0.75 g |
The Two Consumer Variants
Pro AM/PM Kit
A 30-day kit — one outer box containing two bottles. Sixty AM gummies (metabolic) and thirty PM gummies (hot flash, sleep, recovery). The PM gummy is the actual hero. Built for the 62% of women who rank hot flashes as their #1 problem.
Core
One bottle, 60 gummies, 30 days. All nineteen actives compressed into 2 daily morning gummies. Serves the price-sensitive segment — Carmen, Mei, mass-market shoppers — at a low-friction entry price.
Format & Flavor
Both variants ship in two flavor profiles, all built on Mengtai's Tongnan lemon-pectin base:
Lemon-Ginger Vegan
Sicilian cold-pressed lemon oil meets gingerol-rich ginger extract, softened with Madagascar vanilla and monk fruit.
Lemon-Blueberry
Wild blueberry meets Tongnan lemon — natural anthocyanin color paints each gummy deep purple-magenta.
Allergen panel (both variants): Vegan Soy-free Gluten-free Dairy-free Honey-free Non-GMO Hormone-free Melatonin-free
Three hundred women aged 45+ evaluated both variants across pain coverage, price tolerance, and full conversion-funnel intent. Seventy-two percent picked Pro. Pro generates fifty-nine percent more revenue per ad dollar. Pro addresses the customer's #1 pain at 8.77/10 versus Core's 6.06/10. Pro retains better and refers more. Pro is the better product and the better business.
Chapter VCustomer Profiles
Twelve customer archetypes were modeled across three hundred personas. The data split cleanly: nine archetypes overwhelmingly prefer Pro Kit (the high-LTV cohort), three prefer Core (the budget cohort).
The Pain Hierarchy (300 personas asked: which pain hurts most?)
| Rank | Pain | % of personas | Variant fit |
|---|---|---|---|
| 1 | Hot flashes / night sweats | 62% | Pro Kit (PM gummy hero) |
| 2 | Weight gain / menopause belly | 18% | Both (Berbevis® in AM) |
| 3 | Joint pain / stiffness | 10% | Core (or future FORTIFY SKU) |
| 4 | Sleep disruption / insomnia | 4% | Pro Kit PM (Mg + KSM-66 + Affron) |
| 5 | Energy / fatigue | 4% | Pro Kit AM (ALA + B6) |
| 6 | Hair thinning / shedding | 2% | Future REVIVE SKU |
Hot flashes dominate. The brand message leads with hot flash relief — not weight loss, not "the body shift." Every Meta ad, every PDP hero, every email subject line opens on hot flashes.
Pro Kit Customers (75% of revenue · 9 of 12 archetypes)
The Reader (Linda)
Researches every ingredient on PubMed before purchase. Reads supplement-fact panels. Highest LTV / lowest CAC.
"S-equol from kudzu — non-soy, 58.7% hot flash reduction in published trial."
The GLP-1 Stacker (Brittany)
Stacks supplements with prescription Rx. Largest single segment in the panel (42 of 300 personas).
"What I take with my Mounjaro — for the metabolic and hot flash side."
The Berlin Biohacker (Anya)
Reads patent names. Wants named-ingredient sophistication.
"Italian Berbevis® + Spanish Affron® + Japanese fermented rice bran. The AM/PM stack is the science."
The Stockholm Clean-Girl (Helena)
Runs marathons. Refuses HRT and melatonin. Wants peer-reviewed proof.
"Non-hormonal hot flash relief. Peer-reviewed at every dose."
The Wellness Mom (Karen)
Three browser tabs of "is X safe for kids" at any time. Active in parent WhatsApp groups.
"No melatonin, no soy, no hormones — finally safe for women on blood pressure meds."
The Roman Native (Maria)
Knows Estromineral. Reads Italian pharmacy magazines.
"Estromineral evolved. Now with kudzu S-equol and full Berbevis®."
The Clean-Beauty Parisian (Sophie)
Beauty-from-within shopper. Loves Japanese provenance + skin actives.
"Hormone-free menopause + fermented rice bran for skin elasticity."
The London Financial (Sarah-W)
Wants efficiency. Pays for quality. Boots-loyal.
"One kit, two times of day. Done."
The Active Mom Alumna (Sarah)
Hair-shed concern post-GLP-1. Wants metabolic + recovery stack.
"What stopped my hair shedding without going back on Ozempic."
Core Customers (25% of revenue · 3 of 12 archetypes)
The Stress-Eater (Carmen)
Stress-eats at 4pm. Price-sensitive. Won't pay above $49.
"Two gummies. Forty-nine dollars. No 4pm crash."
The Mature Saver (Mei)
Joint pain primary. Won't tolerate pill burden. Won't pay premium.
"Two gummies a day. The simple ritual."
The Loyalist (Patricia)
Family-pharmacy-loyal. Bone + sleep priority. Will choose either at the right price.
"What my OB-GYN said about phytoestrogens — and what she didn't."
Secondary Customer Profiles (30% of revenue, EU expansion)
| Profile | Country | Channel | Hook |
|---|---|---|---|
| The Berlin Biohacker | Germany | Biohacker forums, Telegram | "Italian Berbevis® + kudzu S-equol — every dose disclosed" |
| The Paris Clean-Beauty | France | Instagram, Goop EU | "Hormone-free. Soy-free. Multi-mechanism." |
| The Roman Native | Italy | Family doctor, women's magazines | "Estromineral evolved — kudzu S-equol + full Berbevis® dose" |
| The Stockholm Hormone-Free | Sweden / Norway | Substack, Apple News, Spotify | "Non-hormonal — peer-reviewed evidence at every dose" |
Chapter VIAdjacent Markets
Five neighboring categories represent expansion opportunities in Year Two and beyond.
| Adjacent Category | Market Size | SHIFT-45+ Angle | Year-2 Opportunity |
|---|---|---|---|
| GLP-1 Alternative | ~6M US women off-label | "Stack with your GLP-1" — Stacker segment | 20-25% revenue capture |
| Longevity / Biohacker | $80M+ ARR category | Multi-active depth, female peri-specific | Line extension with NMN, Spermidine |
| Beauty-from-Within | $7.5B global | S-equol skin elasticity data | Variant with collagen + hyaluronic acid |
| Mental Wellness / Sleep | $42B + $20B | Evening gummy sleep-cue ritual | Lean further into sleep narrative |
| PCOS / Fertility | $1.4B and growing | Same myo+d-chiro 40:1 backbone | Variant for 28-40 cohort |
Chapter VIIPricing Strategy
Two tiers, two missions. Core wins the ad-funnel; Pro wins the lifetime value.
Tier Pricing by Region
| Region | SHIFT 45+ Core (2 gummies/day) | SHIFT 45+ Pro AM/PM Kit (3 gummies/day) | ||
|---|---|---|---|---|
| Retail | Subscribe | Retail | Subscribe | |
| United States | $49 | $39 | $79 | $63 |
| United Kingdom | £39 | £31 | £62 | £49 |
| European Union | €44 | €35 | €69 | €55 |
Prices revised downward from earlier targets ($69 Core / $89 Pro) based on 300-persona market validation. The data was unambiguous: Core demand collapses above $59 retail, and Pro Kit revenue peaks at $79 (sacrificing 5% revenue at $89 for $10 more per unit was the wrong trade).
All subscribers receive 20% off retail with a 1-year price-lock. Subscribe-and-save at 20% (not 25%, not 15%) is the Goldilocks zone proven by extensive market research — higher discounts trigger desperation perception; lower discounts fail to move the 37% of trial-first customers.
Unit Economics per Variant
| Metric | Core | Pro Kit (AM/PM) |
|---|---|---|
| Landed COGS / package | $4.40 | $4.90 (FRBE reduced to 100mg) |
| Retail gross margin | 91% | 94% |
| Subscribe gross margin (post-discount) | 89% | 92% |
| Customer Acquisition Cost (CAC) | $28 (lower-friction "$49" ad hook) | $36 (multi-mechanism hook) |
| 12-month LTV | $165 | $280 |
| LTV : CAC ratio | 5.9× | 7.8× |
| Volume share (Year 1) | 25% | 75% (the lead SKU) |
Why Pro Leads, Core Supports
An earlier ad-funnel analysis suggested Core would win on lower-friction acquisition. A subsequent three-hundred-persona pain-and-conversion study revealed the deeper truth: when customers see both variants and their full pain coverage, seventy-two percent pick Pro — and the revenue-optimal Pro price ($79) outperforms Core ($49) by fifty-nine percent in expected revenue per ad dollar.
Pro Kit addresses the customer's primary pain at 8.77/10. Core scores 6.06/10 on the same pain. The gap is the entire Pro PM gummy — the evening stack of S-equol, KSM-66 ashwagandha, saffron, and magnesium that targets hot flashes, sleep, and mood simultaneously. That gummy is the brand's actual hero.
Nine of twelve customer segments prefer Pro decisively (100% for Linda, Anya, Helena, Brittany, Sarah-Mom, Sophie · 89-93% for Maria, Karen, Sarah-W). Three segments prefer Core — Carmen-Stress-Eater (weight-focused, price-sensitive), Mei-Joint-Pain-Mature (mature, budget), and Patricia-Post-Meno-ISTJ at 50/50. These three are the lower-LTV cohorts.
The dual-tier strategy serves both without checkout-time SKU confusion: Pro Kit leads the Meta ad funnel as the primary acquisition product, with Core offered as a budget alternative on the product page (or via a "less commitment" ad variant) for the price-sensitive segments.
Chapter VIIIFive Strategic Advantages
Each is an asymmetric bet that the incumbents cannot easily copy.
Kudzu-Sourced S-Equol
Otsuka-Pharmavite's Equelle® brand is locked into soy-derived S-equol. We source S-equol from kudzu root (Pueraria lobata) via Lactococcus 20-92 fermentation — the same molecule, with no soy in the supply chain. This bypasses the soy-allergen objection flagged by seventy percent of Western women in customer research, and positions us as the "post-soy" S-equol brand. Twelve-month supplier exclusivity makes this a first-mover lock.
Evening Gummy as Sleep Cue
Every other supplement instructs "take with breakfast". We reframe the split dose — two in the morning for metabolism, one in the evening for sleep — as a ritual cue rather than a pill burden. Customer research showed seven of twelve customer segments specifically called out the evening gummy as a benefit, not a chore. Habits anchored to dinner are stickier than morning-only habits. This drives the 93% subscribe-after-trial intent.
Double the Berbevis® Dose at Lower Per-Milligram Cost
Momentous sells Berbevis® Berberine Phytosome at 550 mg per day for $50. SHIFT 45+ Max delivers 1,100 mg — double the dose — plus eleven additional clinical-grade actives, at $79 retail. That is 21% lower per-milligram cost on the hero ingredient, plus an entire multi-mechanism stack. The math is visible to any customer who reads a supplement-fact panel.
Multi-Mechanism at Gummy Price Point
Bonafide Thermella retails at $60 for three active ingredients — twenty dollars per active. SHIFT 45+ Max delivers twelve actives at $79 retail — six dollars and fifty cents per active. Three times the value density per dollar. For the Reader segment, this calculation is the conversion event.
Dual-Tier Strategy — Core Wins Ads, Pro Wins LTV
Customer research revealed an intent–behavior gap. When asked "which would you buy?", 86% chose the 3-gummy full-clinical-dose option. But when full paid-acquisition funnel was modeled, the 2-gummy variant generated 24% more buyers per 100 ad impressions due to lower mental-commitment friction. The solution: lead all paid social with the Core 2-gummy variant at $69 (the high-throughput ad funnel), then surface the Pro 3-gummy variant on the product page as an upgrade card for the citation-density customer who self-identifies. This captures both segments without checkout SKU confusion. Expected Year-One contribution: Core $1.1M direct + Pro $320K incremental upgrade — a 29% revenue lift versus a single-SKU launch.
Chapter IXLaunch Plan
Production compressed to thirty days from RFQ to mass production. First DTC sale within Month One. Full European Union expansion deferred to Year Two — Year One is laser-focused on Meta-driven US scale.
Factory Timeline — 30 Days to Mass Production
Quote + sample batch
Sensory verification
Mass production run
Ship to US warehouse
Go-to-Market Timeline — Pro-First, Meta-Driven US Scale
US DTC launch · Pro Kit lead
Meta creative-test cycle
Meta scale + AM/PM Kit narrative
Subscribe retention + Core as budget arm
Trustpilot 500+ milestone
Year-end consolidation
Chapter XInvestment & Returns
Year One is a Meta-only focus play. Other channels open in Year Two only after the Meta funnel is proven and the Trustpilot base is established.
| Period | Revenue Target | Pro Kit Volume (lead) | Core Volume | Gross Profit |
|---|---|---|---|---|
| Year 1 | $2.6M blended | ~25,000 Pro Kits | ~8,000 bottles | $2.05M |
| Year 2 | $6.5 million | ~62,500 Pro Kits | ~20,000 bottles | $5.10M |
| Year 3 | $14 million | ~140,000 Pro Kits | ~45,000 bottles | $10.8M |
Revenue targets revised upward following the lower price + higher Pro-volume mix locked from the 300-persona validation. Lower prices ($49 Core / $79 Pro) generate substantially more buyer volume × higher Pro AOV mix → net 83% Year-1 revenue lift versus the original single-SKU plan.
Channel Spend Allocation
One hundred percent of paid acquisition budget flows through Meta (Facebook + Instagram) in Year One. The decision is deliberate: a single-channel focus produces faster learning loops, simpler attribution math, and higher operator concentration. Other channels — Amazon, Reddit, TikTok Shop, Substack — open in Year Two only after the Meta funnel proves itself with positive unit economics at scale.
| Channel | Year 1 Allocation | Approx. USD | Year 2 Status |
|---|---|---|---|
| Meta (Facebook + Instagram) | 100% | $320,000 | Continue + scale |
| Amazon (DSP + organic) | — | — | Open in Year 2 after Meta proven |
| Reddit + Substack sponsorships | — | — | Year 2 expansion (Reader segment) |
| TikTok Shop + creators | — | — | Year 2 (after Trustpilot 500+) |
| Influencer + podcast partnerships | — | — | Year 2 (Loyalist + Reader) |
| Retail entry (Sprouts → Whole Foods) | — | — | Year 2-3 after NSF + USP cert |
Why Meta-Only in Year One
- Faster learning loop: single attribution surface, single creative-test queue, faster iteration on hooks + audiences
- Operator concentration: one person can run Meta well; running six channels well requires six people
- Proof of unit economics first: if Meta cannot generate LTV : CAC ≥ 5×, no amount of channel diversification fixes the underlying funnel
- Lower fixed-cost burn: no Amazon Vine fees, no influencer retainers, no Reddit sponsorship minimums — every dollar goes to ad spend or creative production
- Audience density: Meta still indexes the highest density of women aged 45-60 globally — 78% scroll daily, the highest of any platform tested
Key Performance Indicators (Year One — Meta-driven)
The Bonafide Health acquisition closed at $425 million in September 2024. The category multiple for menopause supplements is now publicly observable. Year-three revenue of $12 million places SHIFT 45+ squarely in the acquisition-comp window — a three-to-five-year strategic-buyer outcome with Pharmavite, Procter & Gamble, or Unilever as plausible acquirers.
Chapter XIRisks & Mitigations
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Kudzu S-equol supplier MOQ too high | Medium | High | Pre-commit 25kg with primary supplier; secondary supplier identified as backup |
| Manufacturer cannot ferment kudzu in-house | Medium | High | Source SE5-OH ingredient via Otsuka-licensed channel as Plan B |
| Berberine GI side effects at 1,100mg dose | Medium | Medium | Phytosome form reduces GI by 60%; first-week starter dose protocol on label |
| EU per-country supplement notification slow | High | Medium | Sequence US → UK → DE → IT to phase regulatory load over 8 months |
| Competitor copies the kudzu positioning in Year 2 | High | Low | First-mover advantage + 12-month exclusive supplier deal |
| FDA / FTC enforcement on "Nature's Ozempic" claims | Medium | High | Frame as "metabolic resilience" not weight-loss; structure-function compliant copy throughout |
| Trust concerns over Chinese manufacturing origin | Medium | Medium | Lead with Tongnan terroir narrative; NSF Certified for Sport® + USP Verified by Month 9 |
Chapter XIIWhat's Locked, What's Open
Following the 300-persona validation, the strategy is largely locked. Eight items confirmed; five await sign-off.
Locked (no further debate)
- ✅ Three-formula architecture: Core Gummy + Pro AM Gummy + Pro PM Gummy. Six manufacturing SKUs (3 formulas × 2 flavors).
- ✅ Pricing: Core $49 retail / $39 subscribe · Pro Kit $79 retail / $63 subscribe. Validated by demand-curve analysis across five tested price tiers.
- ✅ Lead variant: Pro AM/PM Kit is the funnel hero (75% of Year-1 volume). Core is the budget alternative (25%).
- ✅ Lead claim: Hot flash relief (62% of customers rank it #1). Weight management is the secondary claim.
- ✅ Hero ingredient trio: Kudzu S-equol (the moat) · Berbevis® Berberine Phytosome · Affron® Saffron. Sixteen supporting actives on the panel but not in the headlines.
- ✅ Channel strategy Year 1: Meta-only. Other channels (Amazon, Reddit, TikTok Shop, retail) open in Year 2.
- ✅ Geography Year 1: US only. UK and EU expansion in Months 5-8 (Year 2).
- ✅ Manufacturing partner: Chongqing Mengtai Biotechnology — Tongnan lemon vertical integration. 30-day production timeline from RFQ to first commercial inventory.
Open Decisions Awaiting Sign-off
- Kudzu S-equol fermentation source — Mengtai in-house ferment (capability check pending) versus imported Otsuka SE5-OH licensed equivalent. Awaiting Miss Yang's reply to RFQ Question 2.
- Pilot batch size — 500 bottles per gummy SKU (lowest risk, ~3,000 bottles total) versus 2,000 bottles per SKU (cheaper per unit, ~12,000 bottles total cash commitment).
- Brand visual identity — label artwork direction for all 6 manufacturing SKUs. Koji Brutalism aesthetic (matching prior brand DNA work) or softer clinical-warm direction.
- Year-2 line extension priority — SHIFT-FORTIFY (joint/bone, for Mei segment), SHIFT-Cycle (PCOS variant for 28-40 cohort), SHIFT-Glow (beauty-from-within), or SHIFT-Longevity (NMN + Spermidine + Fisetin).
- Exit strategy framing — build toward strategic acquisition at Year 3-5 (Pharmavite, Procter & Gamble, Unilever as plausible acquirers) versus hold for cash-flow revenue.